DUSSELDORF, Germany--(BUSINESS WIRE)--Nov 7, 2012--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced plans to showcase the LuViva® Advanced Cervical Scan product at the Medica 2012 International Trade Fair taking place November 14-17 in Dusseldorf, Germany.

In anticipation of its international market launch the company plans to meet with distributors interested in representing LuViva in select markets around the world. The LuViva booth is located in the USA Pavilion in Hall 16/D18-8 in the Dusseldorf Trade Fair Centre.

“We are actively seeking to add qualified distributors to our growing LuViva sales network that have experience introducing innovative technology into the women’s health market,” said Melissa White, International Sales Manager for Guided Therapeutics. “LuViva is attracting superior medical device distributors internationally due to its unique technology and business model which combines a highly valued device with a single-use disposable. While the technology allows distributors to differentiate themselves from competitors, it also provides a viable solution to increasing healthcare quality while lowering healthcare costs in the countries where they operate. We look forward to meeting with companies who are interested in being a part of introducing LuViva to women around the world.” To schedule appointments, contact Melissa White at +1-770-242-8723, EXT 324, or e-mail

LuViva currently has marketing approval from Health Canada and received its first CE Mark, an ISO 60601 Edition 2 Notification, in July. The company plans to file an Edition 3 CE Mark application upon completion of product testing, which is ongoing. Guided Therapeutics was awarded ISO 13485 certification in January, 2011.

About LuViva ® Advanced Cervical Scan LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva ® Cervical Guide single-use patient interface and calibration disposable.

About Medica Medica is an annual medical trade fair held yearly in Dusseldorf, Germany. It is represented as the largest medical product trade show in the world with more than approximately 138,000 visitors and 4,400 exhibitors. For more information, visit About Guided Therapeutics Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company’s first planned product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics has also entered into a partnership with Konica Minolta to develop a non-invasive test for the early detection of esophageal cancer using the technology platform. For more information, visit: www.guidedinc .com.

The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and subsequent quarterly reports.

CONTACT: Investors: Cameron Associates Alison Ziegler, 212-554-5469 or Guided Therapeutics Melissa White, 770-242-8723 KEYWORD: UNITED STATES EUROPE NORTH AMERICA GEORGIA GERMANY INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES ONCOLOGY SOURCE: Guided Therapeutics, Inc. Copyright Business Wire 2012 PUB: 11/07/2012 03:00 AM/DISC: 11/07/2012 03:00 AM